Intellia Therapeutics to Present at March Healthcare Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/23/2026

1. WMT
2. ROST
3. AAP
4. NVDA
5. SPY

6. BABA
7. AVGO
8. SPCX
9. NTES
10. DE

Get Alerts NTLA Hot Sheet

Price: $12.84 +3.22%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

CAMBRIDGE, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will participate at the following upcoming healthcare conferences in March:

Tuesday, March 13, 2018Barclays Capital Global Healthcare ConferenceWho: John Leonard, M.D., Chief Executive Officer and PresidentLocation: Miami, FloridaPresentation Time: 3:50pm EST

Tuesday, March 20, 2018Morgan Stanley Healthcare Corporate Access DayWho: Tom Barnes, Ph.D., Senior Vice President, Innovative SciencesLocation: Boston, MassachusettsOne on one meetings only

Wednesday, March 21, 2018Oppenheimer & Co. 28th Annual Healthcare ConferenceWho: Tom Barnes, Ph.D., Senior Vice President, Innovative SciencesLocation: New York, New YorkPresentation Time: 1:35pm EST

A live webcast of Intellia’s presentations will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Intellia’s website for 14 days following each conference.

About Intellia TherapeuticsIntellia Therapeutics is a leading genome editing company focused on the development of proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.

Investor Contact: Lindsey Trickett Vice President, Investor Relations +1 857-285-6211[email protected]

Media Contact:Jennifer Mound Smoter Senior Vice President, External Affairs & Communications +1 857-706-1071 [email protected]